Chimeric antigen receptor engineered stem cells: a novel HIV therapy.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Immunotherapy

• Publication date

  2017-03-30

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2217/imt-2016-0121PMID 28357916PMCID PMC5618937
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chimeric Antigen Receptor T-Cell Therapy.

  2018cited by this paper
• HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies

  2016cited by this paper
• Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy

  2016cited by this paper
• Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol

  2016cited by this paper
• CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

  2016cited by this paper
• Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID “Meet the Experts” 2015 Workshop Summary

  2016cited by this paper
• T Memory Stem Cells and HIV: a Long-Term Relationship

  2015cited by this paper
• Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity

  2015cited by this paper
• Engineering Cellular Resistance to HIV-1 Infection In Vivo Using a Dual Therapeutic Lentiviral Vector.

  2015cited by this paper
• Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

  2015cited by this paper
• HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells.

  2015cited by this paper
• Ectopic expression of anti-HIV-1 shRNAs protects CD8(+) T cells modified with CD4ζ CAR from HIV-1 infection and alleviates impairment of cell proliferation.

  2015cited by this paper
• CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.

  2015cited by this paper
• Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.

  2015cited by this paper
• Prolonged Antiretroviral Therapy Preserves HIV-1-Specific CD8 T Cells with Stem Cell-Like Properties

  2015cited by this paper
• HIV-1 persistence in CD4+ T cells with stem cell-like properties

  2014cited by this paper
• Expression of Chimeric Receptor CD4ζ by Natural Killer Cells Derived from Human Pluripotent Stem Cells Improves In Vitro Activity but Does Not Enhance Suppression of HIV Infection In Vivo

  2014cited by this paper
• Dynamics of HSPC repopulation in nonhuman primates revealed by a decade-long clonal-tracking study.

  2014cited by this paper
• Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor

  2014cited by this paper
• Manufacture of Gene-Modified Human T-Cells with a Memory Stem/Central Memory Phenotype

  2014cited by this paper
• Improving the safety of cell therapy products by suicide gene transfer

  2014cited by this paper
• Chimeric antigen receptor therapy for cancer.

  2014cited by this paper
• Design and development of therapies using chimeric antigen receptor‐expressing T cells

  2014cited by this paper
• CD19-CAR Trials

  2014cited by this paper
• T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.

  2014cited by this paper
• Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.

  2014cited by this paper
• Functional Comparison of Engineered T Cells Carrying a Native TCR versus TCR-like Antibody–Based Chimeric Antigen Receptors Indicates Affinity/Avidity Thresholds

  2014cited by this paper
• The basic principles of chimeric antigen receptor design.

  2013cited by this paper
• Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

  2013cited by this paper
• Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning

  2013cited by this paper
• HIV‐1 neutralizing antibodies: understanding nature's pathways

  2013cited by this paper
• Antiretroviral drug-related toxicities – clinical spectrum, prevention, and management

  2013cited by this paper
• Introduction of exogenous T-cell receptors into human hematopoietic progenitors results in exclusion of endogenous T-cell receptor expression.

  2013cited by this paper
• Lineage relationship of effector and memory T cells.

  2013cited by this paper
• Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model.

  2013cited by this paper
• IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors.

  2013cited by this paper
• Animal models for HIV/AIDS research

  2012cited by this paper
• Hematopoietic-stem-cell-based gene therapy for HIV disease.

  2012cited by this paper
• Engineering HIV-1-Resistant T-Cells from Short-Hairpin RNA-Expressing Hematopoietic Stem/Progenitor Cells in Humanized BLT Mice

  2012cited by this paper
• Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor–Modified T Cells

  2012cited by this paper
• CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

  2012cited by this paper
• HIV: cell binding and entry.

  2012cited by this paper
• B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

  2012cited by this paper
• Current advances in humanized mouse models

  2012cited by this paper
• Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

  2012cited by this paper
• HIV immune evasion disruption of antigen presentation by the HIV Nef protein.

  2011cited by this paper
• The costs of full suppression of plasma HIV RNA in highly antiretroviral-experienced patients.

  2011cited by this paper
• T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

  2011cited by this paper
• Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

  2011cited by this paper
• Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells

  2011cited by this paper
• Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection.

  2011cited by this paper
• Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

  2010cited by this paper
• Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.

  2010cited by this paper
• A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model.

  2010cited by this paper
• IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo

  2010cited by this paper
• Lentiviral vector gene therapy: effective and safe?

  2010cited by this paper
• Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

  2009cited by this paper
• Engineering Antigen-Specific T Cells from Genetically Modified Human Hematopoietic Stem Cells in Immunodeficient Mice

  2009cited by this paper
• Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

  2009cited by this paper
• Induction of Robust Cellular and Humoral Virus-Specific Adaptive Immune Responses in Human Immunodeficiency Virus-Infected Humanized BLT Mice

  2009cited by this paper
• Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.

  2008cited by this paper
• Optimizing Adoptive Polyclonal T Cell Immunotherapy of Lymphomas, Using a Chimeric T Cell Receptor Possessing CD28 and CD137 Costimulatory Domains

  2007cited by this paper
• CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

  2006cited by this paper
• Occurrence of leukaemia following gene therapy of X-linked SCID

  2003cited by this paper
• A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy.

  2002cited by this paper
• Immune escape of tumors: apoptosis resistance and tumor counterattack

  2002cited by this paper
• Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects.

  2000cited by this paper
• Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection.

  2000cited by this paper
• Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

  1998cited by this paper
• HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes

  1998cited by this paper
• Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells.

  1997cited by this paper
• Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors.

  1994cited by this paper
• Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides.

  1991cited by this paper
• Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

  1989cited by this paper
• Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions.

  1987cited by this paper

• NK Cells Engineered with a Chimeric Antigen Receptor Delay HIV Rebound and Reshape HIV Reservoir Composition

  2026cites this paper
• Searching for a HIV-1 Cure

  2026cites this paper
• Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond

  2025cites this paper
• Navigating the Roadblocks: Progress and Challenges in Cell‐Based Therapies for Human Immunodeficiency Virus

  2024cites this paper
• Rapamycin enhances CAR-T control of HIV replication and reservoir elimination in vivo

  2024cites this paper
• The initial interplay between HIV and mucosal innate immunity

  2023cites this paper
• Strategies for HIV-1 suppression through key genes and cell therapy

  2023cites this paper
• Chimeric Antigen Receptor-Modified Immune Cells for Eradication of HIV Reservoirs

  2022cites this paper
• Human Immunodeficiency Virus Persistence in the Spleen: Opportunities for Pharmacologic Intervention

  2021cites this paper
• Robust CAR-T memory formation and function via hematopoietic stem cell delivery

  2021cites this paper
• Immunity and Viral Infections: Modulating Antiviral Response via CRISPR–Cas Systems

  2021cites this paper
• The role of NK cells in fighting the virus infection and sepsis

  2021cites this paper
• Chronic virus infection drives CD8 T cell-mediated thymic destruction and impaired negative selection

  2020cites this paper
• CAR T cells: Living HIV drugs

  2020influential citation
• Engineering CAR T Cells to Target the HIV Reservoir

  2020cites this paper
• Immunotherapeutics to Treat HIV in the Central Nervous System

  2020cites this paper
• Advances in engineering local drug delivery systems for cancer immunotherapy.

  2020cites this paper
• Long-term survival and differentiation of human thymocytes in human thymus-grafted immunodeficient mice.

  2019cites this paper
• Perturbation of mucosal-associated invariant T cells and iNKT cells in HIV infection

  2019cites this paper
• Chimeric antigen receptor T-cell approaches to HIV cure

  2018cites this paper
• Novel Triterpenone for Treatment of Viral Diseases-HIV Inhibitors.

  2018cites this paper
• Capacity of Human Immunodeficiency Virus Targeting Chimeric Antigen Receptor T Cells to Eliminate Follicular Dendritic Cells Bearing Human Immunodeficiency Virus Immune Complexes

  2017cites this paper
• On the way to find a cure: Purging latent HIV‐1 reservoirs

  2017cites this paper